FLUO FluoGuide A/S

STO · SE · Healthcare · Biotechnology · fluoguide.com

35.00SEK+3.24%Mkt Cap: 54.73M $P/E: —3d ago

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap54.73M USD

Enterprise Value50.88M USD

Revenue (TTM)26.11K USD

Gross Profit26.11K USD

Net Income (TTM)-3.77M USD

Revenue/Share0.02 SEK

Last Price35.00 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees6

CountrySE

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-5.46

PEG—

EV/EBITDA-11.02

EV/Revenue1948.42

P/S2030.19

P/B18.07

EPS (TTM)-4.56

EPS (Forward)-6.21

52W Range

28.0035% of range47.80

52W High47.80 SEK

52W Low28.00 SEK

Profitability

Gross Margin100.00%

Oper. Margin-16211.96%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-72.36%

ROA-44.69%

Growth

Revenue Growth61.40%

Earnings Growth—

Cash Flow & Leverage

Operating CF-3.54M USD

CapEx (TTM)—

FCF Margin-10450.87%

FCF Yield-4.99%

Net Debt-2.14M USD

Net Debt/EBITDA0.46

Balance Sheet

Debt/Equity0.52

Current Ratio1.88

Quick Ratio1.80

Book Value/Sh1.88 SEK

Cash/Share3.05 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)55.46 SEK

Upside (mean)+58.4%

Target Range45.79 SEK – 65.12 SEK

45.79+58.4% to mean65.12

# Analysts2

Ownership

Shares Out.16.35M

Float12.27M

Insiders24.94%

Institutions10.47%

Technical

SMA 5033.25 (+5.3%)

SMA 20036.91 (-5.2%)

Beta0.43

S&P 52W Chg13.94%

Avg Vol (30d)3.98K

Avg Vol (10d)4.41K

Technical Indicators

RSI (14)53.1

MACD0.1071

MACD Signal0.1083

MACD Hist.-0.0012

BB Upper36.42 SEK

BB Middle34.44 SEK

BB Lower32.46 SEK

BB Width11.52%

ATR (14)2.261 SEK

Vol Ratio (20d)0.88x